Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Free Cash Flow: 2023-2025

Historic Free Cash Flow for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to -$10.9 million.

  • Compass Therapeutics' Free Cash Flow rose 2.15% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.1 million, marking a year-over-year increase of 6.29%. This contributed to the annual value of -$44.9 million for FY2024, which is 10.46% down from last year.
  • As of Q3 2025, Compass Therapeutics' Free Cash Flow stood at -$10.9 million, which was up 8.25% from -$11.8 million recorded in Q2 2025.
  • Over the past 5 years, Compass Therapeutics' Free Cash Flow peaked at -$5.9 million during Q3 2023, and registered a low of -$13.9 million during Q1 2024.
  • Moreover, its 3-year median value for Free Cash Flow was -$11.1 million (2024), whereas its average is -$11.0 million.
  • The largest annual percentage gain for Compass Therapeutics' Free Cash Flow in the last 5 years was 25.89% (2024), contrasted with its biggest fall of 87.04% (2024).
  • Quarterly analysis of 3 years shows Compass Therapeutics' Free Cash Flow stood at -$12.4 million in 2023, then climbed by 25.89% to -$9.2 million in 2024, then rose by 2.15% to -$10.9 million in 2025.
  • Its last three reported values are -$10.9 million in Q3 2025, -$11.8 million for Q2 2025, and -$13.2 million during Q1 2025.